Autoimmune Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the autoimmune treatment market size is expected to grow from USD 79.76 billion in 2025 to USD 83.91 billion in 2026 and is forecast to reach USD 108.07 billion by 2031 at 5.19% CAGR over 2026-2031.

This report is Segmented by Treatment Type (Drug Class {Anti-Inflammatory, Anti-Hyperglycemics, Interferons, and More} Surgery {Joint Replacement, Arthrodesis, and More}), Indication (Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Autoimmune Treatment Market Trends and Insights

Age-standardised rise in early-onset autoimmune incidence

Incidence among individuals aged 15-39 has climbed across rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, extending lifetime therapy needs and magnifying the long-run value of safer chronic regimens. Screening programs now target adolescents, while payers prioritise treatments with proven durability. Manufacturers positioned with low-toxicity mechanisms gain larger cumulative revenue because patients initiate therapy earlier. The trend enlarges the addressable population for next-generation biologics and cell therapies, pushing the autoimmune treatment market toward higher long-term volumes.

Biosimilar wave lowering therapy cost-barriers

Adalimumab biosimilars seized 85% of dispensed volume within 18 months of launch, yielding projected system savings of USD 38.4 billion through 2025. Savings free payer budgets for novel assets such as bispecific antibodies or CAR-T constructs. Originators respond with value-added formulations and service packages, raising competitive intensity. Emerging markets that once relied on steroids are now integrating advanced biologics, thereby widening the global penetration of the autoimmune treatment market.

Payer budget fatigue amid oncology biologic spend

Median oncology CAR-T invoice prices exceed USD 400,000 per course, diverting funds from chronic autoimmune lines. The US and EU formularies are tightening prior-authorization criteria for high-cost biologics, introducing step-therapy hurdles that slow uptake. Manufacturers counter with outcomes-based rebates, but near-term volume can lag forecasts, shaving growth from the autoimmune treatment market.

Other drivers and restraints analyzed in the detailed report include:

1. Oral biologics achieving Phase III read-outs
2. Digital-therapeutic-plus-drug adherence programs
3. Slow guideline updates for novel MOAs in emerging markets

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Anti-inflammatory modalities, including TNF blockers, IL-6 antagonists, and JAK inhibitors, accounted for 37.02% of the 2025 global sales. Their broad efficacy across joint, skin, and bowel inflammation cements first-line placement. Fixed-dose subcutaneous pens and once-daily oral tablets reinforce adherence, protecting incumbents from immediate biosimilar cannibalisation. Interferons, however, register an 8.69% CAGR through 2031, driven by novel pegylated and oral formulations entering dermatomyositis and lupus pipelines. New-generation interferons exhibit improved tolerability, extending real-world persistence. The autoimmune treatment market size for interferon-based regimens is expected to climb to USD 9.74 billion by 2031, mirroring label expansions.

Concurrently, bispecific antibodies are emerging as dual-pathway suppressors, attracting blockbuster valuations; Merck paid USD 700 million for Curon's B-cell depleter, CN201, in 2024. Pipeline diversity now includes tolerogenic cell therapies aimed at resetting immune balance instead of chronic suppression. First-in-class candidates in Type 1 diabetes aim to preserve beta-cell function, introducing a preventative approach within the autoimmune treatment market. Although early-stage, these modalities could reshape drug-class mix beyond the forecast window.

Complete Report Scope:

• By Treatment Type
  • Drug Class
    • Anti-Inflammatory
    • Anti-Hyperglycemics
    • NSAIDs
    • Interferons
    • Other Drugs
  • Surgery
    • Joint Replacement (Arthroplasty)
    • Arthrodesis (Joint Fusion)
    • Tendon Reconstruction
• By Indication
  • Rheumatic Disease
    • Proctocolectomy / Colectomy
  • Type 1 Diabetes
    • Thyroidectomy
  • Multiple Sclerosis
    • Others
  • Inflammatory Bowel Disease
  • Other Indications
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America delivered 42.35% of global revenue in 2025, supported by rapid diffusion of innovative modes of action, favourable reimbursement, and a dense clinical-trial ecosystem. The region's flexible accelerated-approval frameworks placed nine autoimmune biologics on the market in the past two years, cementing first-mover advantage. Breakthrough CAR-T programs progress swiftly under FDA Fast Track designations, catalysing investor capital toward next-wave immunomodulation. Digital-health reimbursement parity laws encourage co-prescription of behaviour-change apps, reinforcing medication adherence and lowering relapse-associated costs.

Europe maintains balanced growth as price-volume agreements offset rising treatment intensity. The European Medicines Agency's PRIME pathway shortens approval timelines for high-need assets such as bispecific antibodies, yet national health systems still impose budget caps that lengthen access negotiations. Biosimilar penetration tempers spending, freeing capacity for advanced options. Cross-country consortiums now aggregate demand for niche autoimmune indications, enhancing negotiating leverage and smoothing supply continuity.

Asia-Pacific stands out with an 8.46% CAGR through 2031, driven by demographic expansion, urbanisation, and regulatory harmonisation. China's volume-based procurement slashes biologic prices, yet adds clauses for originators to supply real-world data, fostering evidence-led adoption. Japan's early implementation of cell-processing standards underpins regional CAR-T trials beyond oncology. India and South-East Asia progress slower due to reimbursement fragmentation, but public-private partnerships invest in biologic manufacturing parks that promise local supply resilience. By 2031 the autoimmune treatment market in Asia-Pacific is forecast to reach USD 30.12 billion, providing a vital counterweight to mature regions.

South America and the Middle East & Africa contribute smaller revenue, yet steady health-budget growth and guideline modernisation improve uptake of biosimilars and select originator biologics. Strategies that bundle drug supply with physician-training modules accelerate diffusion in these price-sensitive settings. As a result, the global autoimmune treatment market achieves broader geographic balance, lowering dependence on single-region performance.

1. Abbvie
2. Amgen
3. Johnson & Johnson
4. Eli Lilly and Company
5. Pfizer
6. Roche
7. AstraZeneca
8. Bristol-Myers Squibb
9. Lupin
10. GlaxoSmithKline
11. Novartis Inc
12. Sanofi
13. Biocon
14. CSL Behring
15. Grifols
16. Takeda Pharmaceuticals
17. UCB
18. Regeneron
19. Incyte
20. Horizon Therapeutics
21. Zimmer Biomet
22. Stryker
23. Smiths Group
24. Medtronic
25. New?Med Instruments

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support